JobsinPharma Reciprocal Link

NHS London Procurement Partnership

LPP is a membership organisation, founded and funded by NHS organisations. Working with our members, together we support the NHS to make the most of its purchasing power to maximise investment in patient care - helping trusts to deliver the highest quality services while at the same time ensuring value for money. The NHS spends £18bn across England and Wales. Now, more than ever before, it is vital that every NHS penny is spent wisely to retain, redesign and improve health care. Our team encourages collaboration among acute, mental health, community and primary care organisations. We are committed to helping members achieve their objectives and enabling innovation, increased efficiency, improved patient outcomes and reduced clinical risk. If you're on Twitter or LinkedIn, please follow us - on Twitter we're @LPPNHS and on LinkedIn search for NHS London Procurement Partnership under the Companies tab.

Pharmaceutical industry in the United Kingdom

The pharmaceutical industry in the United Kingdom directly employs around 72,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development.[1][2] In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.[3] The UK is home to GlaxoSmithKline and AstraZeneca, respectively the world's fifth- and sixth-largest pharmaceutical companies measured by 2009 market share.[4] Foreign companies with a major presence in the UK pharmaceutical industry include Pfizer, Novartis,[5] Hoffmann–La Roche and Eisai. One in five of the world's biggest-selling prescription drugs were developed in the UK.[6] Contents [hide] 1 History 1.1 19th century 1.2 20th century 1.3 21st century 2 Research and development 3 Regulation 4 See also 5 References 6 Further reading 7 External links History[edit] Beecham's Clock Tower, constructed in 1877 as part of the Beecham factory in St Helens 19th century[edit] In 1842 Thomas Beecham established the Beecham's Pills laxative business, which would later become the Beecham Group.[7] By 1851 UK-based patent medicine companies had combined domestic revenues of around £250,000.[8] Beecham opened Britain's first modern drugs factory in St Helens in 1859.[7] Henry Wellcome and Silas Burroughs formed a partnership in September 1880, and established an office in Snow Hill in Central London.[9] The London Wholesale Drug and Chemical Protection Society was formed in 1867, which became the Drug Club in 1891, the forerunner of the present-day Association of the British Pharmaceutical Industry.[8] In 1883 Burroughs Wellcome & Co. opened their first factory, at Bell Lane Wharf in Wandsworth, utilising compressed medicine tablet-making machinery acquired from Wyeth of the United States.[9] Burroughs Wellcome & Co. established its first overseas branch in Sydney in 1898.[9] 20th century[edit] The Glaxo department of Joseph Nathan and Co was established in London in 1908.[10] Glaxo Laboratories Ltd absorbed Joseph Nathan and Co in 1947 and was listed on the London Stock Exchange in the same year.[10] In order to satisfy regulations then in place in the UK on the importation of medicines, Pfizer established a compounding operation in Folkestone, Kent in Autumn 1952.[11] Pfizer acquired an 80 acre site on the outskirts of Sandwich in 1954 to enable the expansion of its Kent-based activities.[11] Glaxo acquired Allen and Hanburys Ltd. in 1958.[10] In 1981 the bacterial infection treatment Augmentin (amoxicillin/clavulanate potassium) was launched by Beecham; the anti-ulcer treatment Zantac (ranitidine) was launched by Glaxo; and the antiviral herpes treatment Zovirax (aciclovir) was launched by Wellcome.[10] In 1991 SmithKline Beecham launched Seroxat/Paxil (paroxetine hydrochloride).[10] In June 1993 Imperial Chemical Industries demerged its pharmaceuticals and agrochemicals businesses, forming Zeneca Group plc.[12] In 1995 Glaxo opened a major research and development facility in Stevenage, constructed at a cost of £700 million.[13] In March 1995 the £9 billion acquisition of Wellcome by Glaxo was completed, forming Glaxo Wellcome, in what was the largest merger in UK corporate history to date.[14] BASF completed the acquisition of the pharmaceutical division of The Boots Company in April 1995.[15] In 1997 SmithKline Beecham opened a major new research centre at New Frontiers Science Park in Harlow, Essex.[10] In 1999 Zeneca Group plc and Sweden-based Astra AB merged to form AstraZeneca plc.[16] Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000, with the merger completing in December of that year, forming GlaxoSmithKline plc.[17] 21st century[edit] In February 2001 the Novartis Respiratory Research Centre, the largest single-site respiratory research centre in the world, opened in Horsham.[18] In May 2006 AstraZeneca agreed to buy Cambridge Antibody Technology, then the largest UK-based biotechnology company, for £702 million.[19][20] In April 2007 AstraZeneca agreed to acquire the U.S.-based biotechnology company MedImmune for $15.6 billion.[21] In April 2009 GlaxoSmithKline agreed to acquire Stiefel Laboratories, then the world's largest independent dermatology company, for US$3.6 billion.[22] In June 2009 Eisai opened a major new research and development and manufacturing facility in Hatfield, constructed at a cost of over £100 million.[23][24][25] In November 2009 GlaxoSmithKline and Pfizer combined their respective AIDS divisions into one London-based company, ViiV Healthcare.[26] On 1 February 2011 Pfizer announced that it would be closing its entire research and development facility at Sandwich, Kent within 18–24 months with the loss of 2,400 jobs, as part of a company-wide plan to reduce its spending on research and development.[27][28][29] In March 2013 AstraZeneca announced plans for a major corporate restructuring, including the closure of its research and development activities at Alderley Park, investment of $500 million in the construction of a new research and development facility in Cambridge, and the move of its corporate headquarters from London to Cambridge in 2016.[30][31] The amount of funding received by UK life science companies reached a 10-year high in 2014.[32][33] Research and development[edit] The world headquarters of GlaxoSmithKline in Brentford, London In 2007 the UK had the third-highest share of global pharmaceutical R&D expenditure of any nation, with 9% of the total, behind the United States (49%) and Japan (15%).[34][35] The UK has the largest pharmaceutical R&D expenditure of any European nation, accounting for 23% of the total; followed by France (20%), Germany (19%), and Switzerland (11%).[34] Top 25 UK investors in pharmaceuticals & biotechnology R&D - 2009/10[36] Companya R&D spendingb (£m) 1 GlaxoSmithKline 3,629.00 2 AstraZeneca 2,745.68 3 Shire 346.71 4 Pfizer UK 325.66 5 Roche Products 208.44 6 Eisai Europe 151.13 7 Brinton Healthcare UK Ltd 140.13 8 Eli Lilly and Company 130.21 9 Amgen 127.06 10 Merial 102.42 11 Novartis Pharmaceuticals 90.27 12 John Wyeth & Brother 60.33 13 Bristol-Myers Squibb 55.49 14 Janssen-Cilag 54.37 15 PowderMed 45.57 16 Aventis Pharma 44.92 17 Allergan 37.40 18 Organon Laboratories 36.78 19 Vectura 36.40 20 Antisoma 35.77 21 Boehringer Ingelheim 29.29 22 Genus 28.60 23 BTG 27.00 24 Servier R&D 25.10 25 Ipsen Developments 23.97 26 Renovo 18.07


Wikipedia (Listeni/ˌwɪkɨˈpiːdiə/ or Listeni/ˌwɪkiˈpiːdiə/ wik-i-pee-dee-ə) is a free-access, free-content Internet encyclopedia, supported and hosted by the non-profit Wikimedia Foundation. Those who can access the site can edit most of its articles.[6] Wikipedia is ranked among the ten most popular websites[5] and constitutes the Internet's largest and most popular general reference work.[7][8][9] Jimmy Wales and Larry Sanger launched Wikipedia on January 15, 2001. Sanger[10] coined its name,[11] a portmanteau of wiki[notes 3] and encyclopedia. Initially only in English, Wikipedia quickly became multilingual as it developed similar versions in other languages, which differ in content and in editing practices. The English Wikipedia is now one of more than 200 Wikipedias and is the largest with over 4.9 million articles. There is a grand total, including all Wikipedias, of nearly 35 million articles in 288 different languages.[13] As of February 2014, it had 18 billion page views and nearly 500 million unique visitors each month.[14] Supporters of Wikipedia cite a 2005 survey of Wikipedia published in Nature based on a comparison of 42 science articles with Encyclopedia Britannica, which found that Wikipedia's level of accuracy approached Encyclopedia Britannica‍ '​s.[15] Criticisms of Wikipedia include claims that it exhibits systemic bias, presents a mixture of "truths, half truths, and some falsehoods",[16] and is subject to manipulation and spin.[17]

The British Institute of Regulatory Affairs - The first choice for Regulatory Professionals

The British Institute of Regulatory Affairs - The first choice for Regulatory Professionals. The British Institute of Regulatory Affairs is established as a company limited by guarantee, with offices at No 7, Heron Quays, Marsh Wall, London E14 4JB. The activities of the Institute are directed by the 14 member Governing Body which is elected annually from amongst the Members and Fellows. The membership of the Governing Body consists of the Officers, who are elected annually - the Chairman, Vice Chairman, Treasurer, Secretary, ESRA Operations officer and Chairpersons of the Education and Publications Committees - and the Executive Committee comprising seven other members, one of whom represents ESRA, elected for three-year terms - OFFICIAL SITE LOCATED HERE: Reporting to the Governing Body are a number of other Committees which are responsible for the day-to-day organisation of specific activities: the Membership Committee; the Education Committee and the Publications Committee. Special interest groups representing particular sectors within the membership (e.g. biotechnology, medical devices, etc.) have also been established as Standing Committees. Several regional groups: "BIRA East"; "BIRA North" and others have been formed. These groups offer the opportunity for individuals to meet with other professionals in the same geographical areas. The permanent staff of the Institute includes an Executive Director, who reports to the Governing Body; Meetings Coordinators, the Membership Secretary and the Financial Controller. In addition to the Standing Committees, the Education Committee establishes Working Parties on a standing or an ad hoc basis to take responsibility for the organisation of individual events. The Chairman for each Working Party is nominated by the Chairman of the Education Committee and the Chairman then selects the membership of the Working Party from the available pool of volunteers. The organisation of events is an important part of BIRA's activities, and volunteers for the Working Parties are always welcome. Any member or associate who wishes to get involved in such activities should contact the BIRA office. Questions or comments about this site? Email the Webmaster (scroll to bottom) Breaking News Bookings are now being taken for the *2015 CRED Workshops*. Please see the conference pages for more information or contact the BIRA office. BOOK EARLY TO AVOID DISAPPOINTMENT Conferences and Training BIRA is very active in offering specialised conferences and training courses covering the whole field of Regulatory Affairs. For the current list of venues and dates please click here. Should you Join BIRA? Members and Associate Members of BIRA get generous discounts on the BIRA seminar and course fees and receive regular updates on the regulatory scene through the Regulatory Review publication. They can also access the private membership site to participate in private committees, special interest groups and discussions, seeking and giving advice to peers across the whole spectrum of sustainable eco projects, pharmaceutical and related regulatory matters. BIRA associate membership is available to anyone with an interest in the pharmaceutical regulatory scene. You do not have to be working in the pharmaceutical industry. Full BIRA Membership is available to individuals with appropriate qualifications and / or experience in regulatory affairs. If you would like to join please contact us and we will be delighted to discuss the possibilities with you. Members Members Login here using your login and password. For login help click here

The Institute of Clinical Trials and Methodology

Mission The Institute of Clinical Trials and Methodology is a centre of excellence for clinical trials, meta-analysis and epidemiological studies. It has a particular focus on developing and delivering innovations in methodology that improve and enhance these studies. The goal underpinning the Institute’s work is a commitment to improve health for all. Vision To be a global leader in the design and conduct of clinical research To resolve questions of national and international importance to improve the health of individuals and populations To conduct challenging and innovative clinical studies Engaging a wide range of stakeholders including trialists, clinicians, the public, industry and regulators Develop new and better ways of conducting and analysing studies Training, developing and mentoring the next generation of trialists

The Clinical Sciences Centre (CSC)

The Clinical Sciences Centre (CSC) is based on the Hammersmith campus of Imperial College London. It was established initially in 1994 by the Medical Research Council (MRC) to provide a focus of strength in basic science in a clinical environment with the aims of, firstly, undertaking high quality basic science underpinning our understanding of human disease and, secondly, providing the core competencies required to facilitate the translation of this understanding into improved diagnosis and treatment. The CSC became the third directly-funded MRC Institute in 1998. The present Director, Professor Amanda Fisher, was appointed in August 2008. Imaging Sciences The Imaging Sciences Department was formed in August 2001 to pursue research and post graduate teaching in the field of biomedical imaging and spectroscopy. The department was created by bringing together established groups working on MRI, Ultrasound and RF modeling.

The Pharmaceutical Information and Pharmacovigilance Association (PIPA)

The Pharmaceutical Information and Pharmacovigilance Association (PIPA) exists to support and assist its members in the development of their professional skills and responsibilities. PIPA is the professional organisation for individuals who are involved in the provision and management of information and those involved in the fulfillment of regulatory requirements relating to drug safety.

The Pharmaceutical Licensing Group (PLG)

The Pharmaceutical Licensing Group (PLG) is a not-for-profit association, which is part of a wider network, for executives active in pharmaceutical and biotechnology business development and licensing. It is the premier and original networking group for this industry sector. As a professional association, the overall PLGs mission is to provide its members with a forum for; meeting and discussing matters of general interest networking opportunities promoting best practice in the profession providing training and education The PLG has a network across Europe and allied groups in Canada and Japan. The European PLGs publish the Business Development & Licensing Journal which carries articles on current business issues and news of PLG events. Companies are also offered the opportunity to advertise within the journal. PLG-UK has contracted with Medius Training to manage and administer training courses. Senior licensing executives active in the industry are selected to deliver these courses and all presentations are peer reviewed. The courses are open to all executives interested in healthcare licensing and business development.

European Pharmaceutical Market Research Association | EphMRA

The purpose of EphMRA is to develop and improve standards and techniques in Europe for market research in the field of health and healthcare, and to strengthen the role of the Association in the relevant decision-making processes in order to support its members in their international activities and to create transparency to the general benefit. Our mission, aims and objectives are shared by our sister organisation in the USA, the PBIRG, in order to ensure mutual benefits to all international healthcare companies. EphMRA assists its members to: Improve strategic decision-making throughout all member companies. Enhance the image of marketing research by improving techniques and methods in pharmaceutical marketing research and drives suppliers to provide cost effective solutions. Provide recognised standards by continuously supporting and actively participating in establishing high levels of standards and quality control in pharmaceutical marketing research. The Association plans its direction and activities according to the Strategic Plan formed by the Executive Board and published in 2013.

Pharmaceutical Marketing Research Group (PMRG)

As the leading healthcare marketing research professional association, PMRG serves U.S. and global client researchers and service providers representing pharmaceuticals, biologics, medical/surgical device and diagnostics. The Pharmaceutical Marketing Research Group was founded in 1961. However, there were originally two PMRGs - the Eastern Pharmaceutical Market Research Group (EPMRG) and the Western (WPMRG). All regions east of Chicago were included in the EPMRG and those west of Chicago were part of the WPMRG. The first recorded meeting of the EPMRG took place in the early 1950s at the Waldorf Astoria in New York City. Representatives from about six companies discussed pertinent issues of the day: new product tracking, how to fine-tune forecasting, how to measure promotional impact to determine return on investment, how the new trend of physicians moving into group practices affected prescribing. Today, PMRG is an independent, member-based, not-for-profit association that advances the principles, practice and power of healthcare marketing research by creating a community that supports individual professional development and acts as an advocate for the profession as a whole. Healthcare marketing researchers from around the globe benefit from PMRG's:

The Pharmaceutical Marketing Society

The PM Society seeks to promote marketing excellence throughout the healthcare and life science industries, promising to educate, inform and facilitate networking through its various channels â online, print and at live events. The PM Society was established over 30 years ago, and in 2012 we presented a new look, introducing Interest Groups aligned to the current challenges and issues facing todayâs marketers â Market Access, Digital, NHS Partnerships, Patient Engagement, Personal Career Development. Alongside its two highly regarded Award schemes â PM Society Advertising Awards and the Digital Media Awards â these groups are led by experts in the field. The not-for-profit Society is run largely by volunteers with a skeleton staff working to support its growing membership from over 230 companies operating in the UK. To achieve our aims we work closely with media partners, third party suppliers and associations to provide quality content, workshops and learning for members. PriMe, the PM Societyâs flexible modular training programme is developed by the industry for the industry addressing the specific training needs for pharmaceutical marketing and associated life sciences disciplines. Working with The MSI Consultancy, courses run throughout the year and are tailored for those new to marketing, anyone needing a refresher and advanced modules for the more experienced marketer. For more information see the PriMe website. - See more at:

FDA Organization

FDA Organization FDA is an agency within the Department of Health and Human Services. The FDA's organization consists of the Office of the Commissioner and four directorates overseeing the core functions of the agency: Medical Products and Tobacco, Foods, Global Regulatory Operations and Policy, and Operations.

Society of Quality Assurance (SQA)

Who We Are SQA is an association of over 2,300 QA professionals in over 30 countries who are dedicated to implementing Good Clinical Practices (GCPs), Good Laboratory Practices (GLPs) and Good Manufacturing Practices (GMPs) in industry, government, academia and consulting. What We Do The professionals in this Society are challenged to perform duties relating to quality assurance of: Nonclinical laboratory studies within the scope of the U.S. Environmental Protection Agency (EPA) and the U.S. Food and Drug Administration (FDA) Good Laboratory Practice (GLP) regulations and international standard for nonclinical laboratory studies prepared by the Organization for Economic Cooperation and Development; Clinical investigations within the scope of FDA Good Clinical Practice regulations, EPA regulations for the Protection of Human Subjects, United States Department of Agriculture regulations for veterinary biologics and international standards for clinical investigations prepared by the International Conference on Harmonization (ICH) and the Veterinary International Conference on Harmonization (VICH); and FDA current Good Manufacturing Practice regulations and the international quality standards prepared by the ICH, VICH and ISO (International Organization for Standardization). The professionals also promote a quality culture by encouraging integrity and promoting quality systems in all scientific research.

The Research Quality Association (RQA)

The Research Quality Association (RQA) was formerly called BARQA, the British Association of Research Quality Assurance and was changed in December 2012. For information on the RQA organisation structure and the RQA Office structure please click on the graphic opposite. As an Association dedicated to informing and advancing its members, we provide status and visibility for individuals concerned with the quality of research and development concerning pharmaceuticals, agrochemicals, chemicals and medical devices. Since its inception in 1977 the Association has grown and developed to reflect regulatory changes, the impact of regulatory inspection and the changing structure and needs of industry.

Quality Assurance Association (QAA)

We would like to acquaint you with the Quality Assurance Association (QAA). This is an organization of professionals from wholesalers, retailers, manufacturers, laboratories, government, suppliers, and others. The QAA is a non-profit organization dedicated to providing information and training related to the quality of Private Label products. QAA was founded in 1988 on the vision of Herb Pease Sr. and the help of eight other individuals. He believed that he could spark interest in a new professional association devoted to quality excellence in the private label industry by bringing a group of people together for a Quality Assurance Seminar. As a result of these efforts, the Quality Assurance Association was presented during the 1989 Private Label Manufacturersâ Show, in Rosemont, Illinois. The following points are offered to provide a top-line view of the QAA: Information: Through our newsletters and conferences, members receive practical information about products, testing and regulations affecting the private label industry. Networking: QAA provides multiple opportunities to share information and experiences with like-minded professionals. Training: The ability to meet workplace challenges and maintain the highest levels of technical expertise in todayâs fast-paced world is one of our biggest challenges. At our technical conferences, you will gain the most current information available. The speakers who are invited to our conferences are all industry or government experts who can provide insights into todayâs issues affecting your job. Focus: The focus of QAA is on industry-specific information and professional connections to help gain the resources to find Solutions.

The Royal Pharmaceutical Society

The Royal Pharmaceutical Society believes that pharmacists should be: The recognised professional member of the healthcare team responsible for choosing pharmacotherapy The universally accessible frontline clinical provider of all aspects of pharmaceutical care The healthcare professional entrusted by patients to take care of their every pharmaceutical need The recognised expert professional for medicines governance, information and management The guardian of patient safety and welfare, maximising the benefits of medicines and minimising the risks caused by adverse effects The leader in pharmaceutical innovation, research and developments of medicines, and of the delivery of pharmaceutical services The patientâs safeguard in the research, design, manufacture and supply of quality assured medicines The educator of all health professionals, the public and patients on the safe and effective use of medicines Accessible to all patients as a source of advice on health improvement and well-being

The Society for Clinical Data Management (SCDM)

The Society for Clinical Data Management is a non-profit, international organization of 2,400+ members founded to advance the discipline of clinical data management. SCDM members are charged with promoting quality and excellence in data management and are dedicated to the development, support and advancement of clinical data management professionals. SCDM is organized exclusively for educational and scientific purposes. Through collaborations and partnerships with other professional organizations, The Society for Clinical Data Management creates a network of professionals driving the industry forward on multiple fronts: technological, regulatory, procedural and personnel. Educational offerings, available both in-person and on-line, seek to provide the fundamental training for clinical data management skills. - See more at: Us/What is Scdm.aspx#sthash.s8M3jEym.dpuf

The Association for Clinical Data Management (ACDM)

The Association for Clinical Data Management (ACDM) was founded in 1987. We have a large, diverse membership and aim to lead the development and appreciation of the essential activities of the Clinical Data Management profession. We represent and support professionals involved with managing clinical data from within the pharmaceutical, biotechnology and academic research fields. ACDM provides explicit settings for the membership to develop standards within the profession. We also seek to enhance the individual skills, knowledge and professional development of our members. The intent is to equip them to participate more effectively in the mainstream of drug development. At the hub of ACDM activities, our website offers a diverse, valuable resource for all levels of professional people managing clinical data. We aim to promote best practices, share knowledge and assist with the professional development of our growing membership. ACDM is an independent, non profit making organisation with an international perspective. Click here to view information about ACDM and membership benefits

The Association of Clinical Research Professionals (ACRP)

The Association of Clinical Research Professionals (ACRP) Our Mission: To provide global leadership to promote integrity and excellence for the clinical research profession. The Association of Clinical Research Professionals (ACRP) is the primary resource for clinical research professionals in the pharmaceutical, biotechnology and medical device industries, and those in hospital, academic medical centers and physician office settings. Headquartered in Alexandria, Virginia, ACRP was founded in 1976 to address the distinct educational and networking needs of research nurses and others who supported the work of clinical investigations. With its own professional society came the recognition of a new distinctive profession â that of the clinical researcher. More than 35 years later, ACRP is a global association comprised of the largest community dedicated to clinical research and development.

The Regulatory Affairs Professionals Society (RAPS)

The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Founded in 1976, RAPS helped establish the regulatory profession and continues to actively support the professional and lead the profession as a neutral, non-lobbying nonprofit organization. RAPS offers education and training, professional standards, publications, research, knowledge sharing, networking, career development opportunities and other valuable resources, including Regulatory Affairs Certification (RAC), the only post-academic professional credential to recognize regulatory excellence. RAPS is headquartered in suburban Washington, DC, with offices in Europe and Asia, and chapters and affiliates worldwide.

The Organisation for Professionals in Regulatory Affairs (TOPRA)

Founded in 2004, TOPRA is the professional membership body for individuals who work in healthcare regulatory affairs across Europe â be it in pharmaceuticals, medical devices or veterinary medicines.

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

Representing the research-based pharmaceutical industry in Geneva Founded in 1968, the IFPMA is a global, non-profit, nongovernmental organization. With members across the globe and a secretariat based in Geneva, Switzerland, the IFPMA represents the research-based pharmaceutical industry, including the biotechnology and vaccine sectors. Our members comprise leading international companies as well as national and regional industry pharmaceutical associations in both developing and developed countries. Our primary role is to improve global health by representing our members in dialogue with intergovernmental bodies, nongovernmental organizations, Geneva-based missions of national governments, civil society organizations and others. The IFPMA has several expert committees and working groups which leverage industry expertise to develop effective approaches to health issues. Its governing bodies are the IFPMA Council, a group of elected representatives from member companies and associations, and the IFPMA Assembly, which comprises the entire membership. The President of the IFPMA is elected by the Council for a two-year term and is chosen from among the Chief Executive Officers of member companies. The IFPMA has two Vice Presidents, also elected for a period of two years. - See more at:

European Medicines Agency

The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.



Recipharm launches a senior unsecured convertible


Additional Links

The purpose of EphMRA is to develop and improve st

JobsinPharma Connects

© 2021 Jobsinpharma - 4ward Technologies Ltd All rights reserved.